List of Excipients in Branded Drug RYDAPT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	RYDAPT	rydapt	0078-0698	.ALPHA.-TOCOPHEROL
Novartis Pharmaceuticals Corporation	RYDAPT	rydapt	0078-0698	ALCOHOL
Novartis Pharmaceuticals Corporation	RYDAPT	rydapt	0078-0698	CARMINIC ACID
Novartis Pharmaceuticals Corporation	RYDAPT	rydapt	0078-0698	CORN OIL

RYDAPT Excipient Strategy and Commercial Opportunities for Midostaurin

Last updated: September 25, 2026

Rydapt is a lipid-based softgel formulation of midostaurin designed to address the drug’s poor aqueous solubility and exposure variability. The commercial opportunity is concentrated in bioequivalent generic formulations, excipient and lipid-fill supply, manufacturing technology, and differentiated oral delivery systems. Rydapt is a small molecule, so biosimilar competition does not apply. Generic applicants would pursue an abbreviated new drug application, with formulation similarity, food-effect performance, softgel manufacturing, and patent litigation as the main barriers.

What is Rydapt and how is it administered?

Rydapt contains midostaurin, a multi-kinase inhibitor that inhibits FLT3 and KIT signaling. The FDA-approved product is a 25 mg oral softgel capsule.

Attribute	Rydapt
Active ingredient	Midostaurin
Strength	25 mg per capsule
Dosage form	Liquid-filled softgel capsule
Sponsor	Novartis Pharmaceuticals Corporation
FDA approval	2017
Main indications	Newly diagnosed FLT3-mutated acute myeloid leukemia with standard chemotherapy; advanced systemic mastocytosis
Administration	Taken orally with food
Main metabolic pathway	CYP3A4
Generic pathway	ANDA
Biosimilar pathway	Not applicable
Key formulation issue	Low aqueous solubility and food-dependent exposure

For AML, Rydapt is administered with induction and consolidation chemotherapy and then as maintenance therapy in the approved regimen. For advanced systemic mastocytosis, it is administered as monotherapy. The product label directs administration with food, which is commercially important because the food effect is connected to absorption and formulation performance rather than patient convenience alone (FDA, 2023).

What excipients are used in Rydapt capsules?

The Rydapt formulation uses a lipid and surfactant system to keep midostaurin solubilized in the gastrointestinal tract. The U.S. prescribing information identifies the capsule contents as including macrogolglycerol hydroxystearate, polysorbate 80, mono- and diglycerides of corn oil, and ethanol. The shell contains gelatin, glycerin, titanium dioxide, and iron oxide colorants (FDA, 2023).

Formulation component	Reported role
Macrogolglycerol hydroxystearate	Lipidic solubilizer and vehicle
Polysorbate 80	Surfactant and dispersion aid
Mono- and diglycerides of corn oil	Lipid vehicle
Ethanol	Co-solvent
Gelatin	Softgel shell-forming polymer
Glycerin	Plasticizer for the shell
Titanium dioxide	Opacifier
Iron oxides	Capsule coloring

The formulation is not a conventional powder-filled capsule. Its liquid-fill architecture is relevant to generic development because a solid oral formulation with a different excipient system may not reproduce the same dissolution, absorption, or food-effect profile.

Why does Rydapt use a lipid-based excipient system?

Midostaurin has limited water solubility. A lipid-based formulation can improve apparent solubility, support dispersion after ingestion, and reduce the risk that dissolution becomes the rate-limiting step for absorption.

The formulation also supports oral delivery across two clinically different settings:

1. Combination treatment with chemotherapy in AML.
2. Long-term oral monotherapy in systemic mastocytosis.

The food instruction indicates that administration conditions affect exposure. The FDA label reports higher midostaurin exposure when administered with a standard meal compared with fasting conditions. A generic formulation that performs adequately under fasting conditions but produces a materially different fed-state profile could face bioequivalence or labeling complications (FDA, 2023).

The excipient strategy therefore has four technical objectives:

• Maintain midostaurin in a solubilized or readily dispersible state.
• Control precipitation after dilution in gastrointestinal fluids.
• Limit degradation during storage.
• Produce consistent exposure under the labeled fed condition.

What formulation risks are associated with Rydapt excipients?

The principal risks concern chemical stability, capsule compatibility, tolerability, and manufacturing reproducibility.

Lipid and surfactant stability

Polysorbate 80 and lipid excipients can undergo oxidation or hydrolysis. Peroxide formation may affect the active ingredient or create degradation products. The risk profile depends on excipient grade, supplier controls, oxygen exposure, water content, antioxidant strategy, and container closure.

Macrogolglycerol hydroxystearate can vary in composition across grades. Such variability can affect viscosity, fill weight, dispersion, and dissolution. A generic manufacturer would need tight incoming-material specifications rather than relying only on compendial identity testing.

Ethanol retention

Ethanol functions as a co-solvent, but its concentration can change during manufacturing and storage. Softgel encapsulation, drying, shell permeability, and packaging conditions can influence ethanol loss. An ethanol-containing fill also creates process and facility requirements related to solvent handling and fill-weight control.

Gelatin shell performance

Gelatin shell properties affect oxygen and moisture transmission, brittleness, dissolution, and mechanical integrity. Shell performance can change with gelatin source, bloom strength, glycerin content, residual moisture, storage temperature, and humidity.

The gelatin shell also creates commercial constraints for vegetarian, vegan, halal, and kosher markets. A non-gelatin shell could differentiate a product, but it would require separate stability, dissolution, process-validation, and possibly bioequivalence work.

Gastrointestinal tolerability

The product label reports gastrointestinal adverse events, including nausea and vomiting, in the Rydapt treatment population. Excipients are not the sole cause of those events, because midostaurin and concomitant chemotherapy are major contributors. Still, a formulation that increases local irritation or causes a faster concentration spike could be commercially unattractive in AML and systemic mastocytosis.

What formulation alternatives could compete with Rydapt?

The most credible alternatives are other liquid-filled oral systems rather than a simple powder-filled capsule.

Alternative	Commercial rationale	Main technical barrier
Generic liquid-filled softgel	Closest route to reference formulation	Excipient matching, fill process, stability, bioequivalence
Hard capsule with liquid or semisolid fill	Potentially simpler shell sourcing	Leakage, seal integrity, dissolution, moisture control
Self-emulsifying drug-delivery system	May improve dispersion and reduce precipitation	Surfactant tolerability and food-effect matching
Amorphous solid dispersion	Could remove or reduce liquid fill	Physical stability and dose loading
Spray-dried dispersion	May support a conventional capsule or tablet	Scale-up, residual solvent, recrystallization
Lipid nanoparticle or advanced lipid system	Possible differentiated exposure profile	Regulatory complexity and manufacturing cost
Oral suspension	Potential pediatric or swallowing advantage	Dose uniformity, physical stability, preservative system
Modified-release capsule	Could address tolerability or exposure peaks	Clinical bridging and potential new-drug requirements

A generic manufacturer is likely to prioritize a formulation that is close enough to Rydapt to reduce development risk. A substantially different delivery system may create a differentiated product but can increase regulatory requirements and litigation exposure.

How strong is the Rydapt formulation moat?

The strongest protection is technical rather than purely excipient-specific. A competitor can often avoid literal infringement by changing the precise ratios or substituting functionally similar excipients. The harder problem is reproducing the overall performance of the reference product.

The practical formulation moat has five elements:

1. Midostaurin’s low solubility.
2. Dependence on a lipid and surfactant system.
3. Administration with food.
4. Softgel manufacturing know-how.
5. Exposure to CYP3A4-mediated interactions and variable patient conditions.

A generic applicant does not need to copy every excipient. It must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. That creates room for excipient substitution, but the substitution must not materially alter release or exposure.

The most defensible formulation know-how is likely to reside in process parameters, not the public ingredient list. Examples include order of addition, temperature control, deaeration, fill viscosity, encapsulation speed, drying conditions, and storage controls.

What patents protect Rydapt and its excipient strategy?

Rydapt’s protection should be separated into four categories:

Protection category	Relevance to midostaurin
Compound patents	Protect the active molecule and related chemical matter
Treatment patents	Cover use in FLT3-mutated AML or systemic mastocytosis
Formulation patents	May cover solubilized oral compositions, dosage forms, or excipient combinations
Manufacturing patents	May cover preparation, purification, or formulation processes

The original compound patent estate is older than the product approval and may no longer be the principal barrier. Later method-of-use and formulation patents can have longer effective lives. FDA Orange Book listings, patent-term adjustments, pediatric extensions, and any litigation settlements determine the practical generic-entry date. Those records must be evaluated separately from the Rydapt label because the label does not establish patent scope or enforceability (FDA, n.d.-a).

When does Rydapt lose exclusivity?

Rydapt’s regulatory exclusivity and patent exclusivity do not expire on the same date. FDA approval in 2017 created a separate regulatory history from the underlying patent estate. Generic entry depends on the latest enforceable patent and any settlement terms, not simply the approval anniversary.

An ANDA applicant can file with a Paragraph IV certification against a listed patent. If the patent holder sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments (FDA, n.d.-b).

What Paragraph IV challenges and litigation risks exist for Rydapt?

The principal litigation risks for a Rydapt generic are likely to involve:

• Method-of-use patents covering FLT3-mutated AML treatment.
• Use in advanced systemic mastocytosis.
• Formulation claims covering a liquid-filled or lipid-based dosage form.
• Infringement allegations based on product composition or manufacturing steps.
• Label-slimming disputes if a generic seeks to omit patented indications.

A generic applicant may attempt a section viii statement to omit a patented use from its labeling. That strategy is more difficult when the protected indication is central to the commercial market or when prescribing and reimbursement practices make indication separation impractical.

Litigation exposure is commercially significant because Rydapt has two principal markets. A narrow carve-out may be workable for one indication but not the other. Settlement agreements could permit an earlier launch while restricting the generic label, manufacturing route, or launch date. Public FDA approval records and federal court dockets are the relevant sources for confirming current litigation and settlement status.

What is the FDA regulatory status of Rydapt?

Rydapt is FDA-approved for:

• Newly diagnosed FLT3-mutated AML in adults, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, followed by Rydapt maintenance.
• Adults with aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia (FDA, 2023).

The product is subject to boxed-warning-level clinical concerns relating to embryo-fetal toxicity in the prescribing information and carries clinically important drug-interaction restrictions involving strong CYP3A4 inhibitors and inducers. These restrictions can affect formulation strategy because altered absorption or higher systemic exposure may increase the difficulty of positioning a differentiated product.

What commercial opportunities exist for Rydapt excipients?

Excipient supply

The most immediate opportunity is supply of high-purity lipid and surfactant excipients suitable for liquid-filled softgels. Suppliers can compete through:

• Low-peroxide grades.
• Tighter viscosity specifications.
• Improved batch-to-batch consistency.
• Global regulatory documentation.
• Animal-origin-free or religiously certified materials.
• Better stability in ethanol-containing fills.

Excipients that are technically interchangeable in a monograph may not be interchangeable in the finished product. This creates value for suppliers with reference-product experience and strong change-control systems.

Generic formulation licensing

A developer with a validated solubilization platform could license:

• A Rydapt-equivalent lipid fill.
• A hard-capsule liquid-fill process.
• A self-emulsifying formulation.
• A non-gelatin shell system.
• Stability packages and analytical methods.

Licensing value will depend on demonstrated fed-state bioequivalence, not simply laboratory solubility data.

CDMO manufacturing

Softgel manufacturing is a specialized capability. CDMOs with compatible equipment, solvent controls, encapsulation capacity, and stability infrastructure can target generic and regional Rydapt opportunities. The highest-value providers will offer development through commercial scale rather than only capsule encapsulation.

Lifecycle management

Potential lifecycle products include:

• Lower-volume capsules for dose titration.
• A swallowing-friendly oral liquid.
• A non-gelatin capsule.
• A formulation with reduced ethanol.
• A product optimized for patients receiving antiemetic therapy.
• Regional products adapted to local excipient restrictions.

Each option would face a different regulatory pathway. A lower-strength capsule may be more commercially realistic than a new delivery system because it could support dosing flexibility without requiring a new clinical value proposition.

How does Rydapt compare with other targeted AML drugs?

Rydapt competes in FLT3-mutated AML with other FLT3-directed therapies, including Xospata, whose active ingredient is gilteritinib, and Vanflyta, whose active ingredient is quizartinib. The products differ in indication, treatment setting, dosage form, dosing schedule, and patent profile.

Product	Active ingredient	Main formulation implication
Rydapt	Midostaurin	Lipid-based liquid-filled softgel; food administration
Xospata	Gilteritinib	Conventional tablet platform; different formulation and generic strategy
Vanflyta	Quizartinib	Tablet platform with distinct safety and dosing considerations

Rydapt’s excipient opportunity is therefore more specialized than a standard tablet opportunity. Its commercial value lies in lipid formulation expertise and softgel execution. Competing AML products may have different patent barriers, but they do not provide direct formulation substitutes for midostaurin.

What generic launch scenarios exist for Rydapt?

Scenario	Timing driver	Commercial outcome
No successful Paragraph IV challenge	Latest patent or settlement date	Delayed generic entry
Early settlement launch	Negotiated entry date	Limited competition before full patent expiry
Formulation design-around	Non-infringing excipient system	Potential earlier launch, higher development risk
Label carve-out	Patented indication omitted	Reduced addressable market
Multiple generic entrants	Shared ANDA timing	Rapid price erosion and supply competition
Regional launch only	Local patent and regulatory differences	Selective market entry

AML volume is more variable than chronic solid-tumor volume because treatment is concentrated in specialized centers and is frequently combined with hospital-administered chemotherapy. Systemic mastocytosis creates a smaller but potentially more durable oral specialty market. A generic strategy should model both markets separately.

What is the revenue exposure to Rydapt competition?

Rydapt’s revenue exposure is tied to:

• The size of the FLT3-mutated AML population.
• Duration of maintenance therapy.
• Systemic mastocytosis prevalence and treatment duration.
• Competition from other FLT3 inhibitors.
• Generic entry timing.
• Payer restrictions and specialty-pharmacy distribution.
• The ability of generic manufacturers to reproduce the softgel formulation at scale.

Novartis reports Rydapt sales in its annual reporting, but revenue figures should be taken from the latest company filing because currency translation, geographic mix, and portfolio reporting can change by year (Novartis, 2024). The commercial decline after generic entry is likely to be faster in AML if several ANDA products launch simultaneously. Systemic mastocytosis may show slower erosion because of lower patient volumes, specialist prescribing, and treatment continuity.

What geographic coverage matters for Rydapt excipient opportunities?

The United States is the most important market for Orange Book-driven generic competition. Europe requires separate assessment of the centralized marketing authorization, supplementary protection certificates, national enforcement, and European patent validation. Japan, Canada, China, and emerging markets have different patent, regulatory, and excipient requirements.

Geographic differentiation may be possible through:

• Gelatin-free capsules in markets with animal-origin restrictions.
• Alternative colorants where local regulations differ.
• Excipient substitutions that address local supply constraints.
• Regional CDMO production.
• Separate patent and regulatory filing strategies.

A formulation that is commercially viable in the United States may require different excipient documentation or shell specifications in Europe and Asia.

Key Takeaways

• Rydapt is a 25 mg midostaurin liquid-filled softgel.
• Its formulation relies on lipid and surfactant excipients, including macrogolglycerol hydroxystearate, polysorbate 80, mono- and diglycerides of corn oil, and ethanol.
• The main technical barrier is reproducing exposure and dissolution under fed conditions.
• Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.
• Paragraph IV litigation may target method-of-use, formulation, or manufacturing patents.
• The strongest commercial opportunities are low-peroxide excipient supply, softgel CDMO services, generic formulation licensing, and differentiated shell or delivery systems.
• A non-gelatin or hard-capsule product could differentiate commercially but would carry added bioequivalence and stability risk.
• AML and systemic mastocytosis should be modeled as separate markets because their treatment duration, prescribing base, and generic erosion dynamics differ.

FAQs About Rydapt Excipients and Commercial Strategy

Does Rydapt contain polysorbate 80?

Yes. The U.S. prescribing information identifies polysorbate 80 as an inactive ingredient in the capsule fill. It functions as a surfactant in the lipid-based formulation (FDA, 2023).

Is Rydapt a tablet or a softgel?

Rydapt is a 25 mg liquid-filled softgel capsule. The softgel format is relevant to generic manufacturing because it requires controlled liquid filling, encapsulation, drying, and stability processes.

Can a generic Rydapt use different excipients?

Yes. A generic applicant generally does not need to duplicate every inactive ingredient, but the product must satisfy applicable pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements. A different excipient system may increase development risk if it changes dissolution or fed-state exposure.

Is there a biosimilar version of Rydapt?

No. Midostaurin is a chemically synthesized small molecule. Competitive products would be generics submitted through an ANDA or, for a substantially modified product, a different FDA pathway.

Which Rydapt excipient opportunity has the highest commercial value?

The highest-value opportunity is a validated lipid-fill platform that delivers fed-state bioequivalence with robust stability and scalable softgel manufacturing. Commodity excipient sales alone are less defensible than a combined excipient, process, analytical, and CDMO offering.

References

1. European Medicines Agency. (2017). Rydapt: EPAR - product information. https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt

2. U.S. Food and Drug Administration. (2023). Rydapt (midostaurin) prescribing information. Novartis Pharmaceuticals Corporation. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207360s009lbl.pdf

3. U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.-b). Paragraph IV drug product applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-drug-product-applications

5. Novartis AG. (2024). Annual report 2023. https://www.novartis.com/investors/financial-data/annual-reporting